Geneva Capital Management’s Bio-Techne TECH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $71.5M | Sell |
1,012,077
-230,966
| -19% | -$12.5M | 1.64% | 20 |
|
|
2026
Q1 | $65M | Buy |
1,243,043
+152,548
| +14% | +$9.16M | 1.38% | 27 |
|
|
2025
Q4 | $64.1M | Sell |
1,090,495
-94,513
| -8% | -$5.74M | 1.2% | 29 |
|
|
2025
Q3 | $65.9M | Sell |
1,185,008
-91
| -0% | -$4.87K | 1.13% | 32 |
|
|
2025
Q2 | $61M | Buy |
1,185,099
+86,380
| +8% | +$4.34M | 1.02% | 35 |
|
|
2025
Q1 | $64.4M | Buy |
1,098,719
+8,784
| +0.8% | +$595K | 1.2% | 27 |
|
|
2024
Q4 | $78.5M | Sell |
1,089,935
-14,375
| -1% | -$1.06M | 1.36% | 26 |
|
|
2024
Q3 | $88.3M | Buy |
1,104,310
+17,114
| +2% | +$1.29M | 1.47% | 21 |
|
|
2024
Q2 | $77.9M | Buy |
1,087,196
+7,183
| +0.7% | +$529K | 1.42% | 23 |
|
|
2024
Q1 | $76M | Buy |
1,080,013
+757
| +0.1% | +$54.2K | 1.34% | 26 |
|
|
2023
Q4 | $83.3M | Buy |
1,079,256
+9,322
| +0.9% | +$614K | 1.57% | 22 |
|
|
2023
Q3 | $72.8M | Sell |
1,069,934
-1,583
| -0.1% | -$125K | 1.53% | 25 |
|
|
2023
Q2 | $87.5M | Buy |
1,071,517
+1,260
| +0.1% | +$101K | 1.72% | 16 |
|
|
2023
Q1 | $79.4M | Buy |
1,070,257
+10,757
| +1% | +$829K | 1.62% | 18 |
|
|
2022
Q4 | $87.8M | Sell |
1,059,500
-6,072
| -0.6% | -$482K | 1.97% | 11 |
|
|
2022
Q3 | $75.7M | Buy |
1,065,572
+40,864
| +4% | +$3.53M | 1.75% | 13 |
|
|
2022
Q2 | $88.8M | Sell |
1,024,708
-5,900
| -0.6% | -$553K | 2.04% | 8 |
|
|
2022
Q1 | $112M | Sell |
1,030,608
-3,100
| -0.3% | -$320K | 2.16% | 4 |
|
|
2021
Q4 | $134M | Sell |
1,033,708
-23,520
| -2% | -$2.88M | 2.16% | 6 |
|
|
2021
Q3 | $128M | Sell |
1,057,228
-354,696
| -25% | -$43.2M | 2.17% | 5 |
|
|
2021
Q2 | $159M | Sell |
1,411,924
-21,772
| -2% | -$2.29M | 2.59% | 2 |
|
|
2021
Q1 | $137M | Sell |
1,433,696
-178,136
| -11% | -$16.3M | 2.34% | 2 |
|
|
2020
Q4 | $128M | Buy |
1,611,832
+46,292
| +3% | +$3.35M | 2.17% | 5 |
|
|
2020
Q3 | $97M | Buy |
1,565,540
+35,492
| +2% | +$2.31M | 2% | 7 |
|
|
2020
Q2 | $101M | Buy |
1,530,048
+41,996
| +3% | +$2.51M | 2.19% | 7 |
|
|
2020
Q1 | $70.5M | Buy |
+1,488,052
| New | +$74.4M | 2.01% | 6 |
|
|
2014
Q3 | $19.1M | Sell |
814,772
-18,448
| -2% | -$432K | 0.56% | 68 |
|
|
2014
Q2 | $19.3M | Buy |
833,220
+53,156
| +7% | +$1.17M | 0.47% | 66 |
|
|
2014
Q1 | $16.6M | Buy |
780,064
+98,136
| +14% | +$2.21M | 0.39% | 73 |
|
|
2013
Q4 | $16.1M | Buy |
681,928
+152,424
| +29% | +$3.3M | 0.37% | 78 |
|
|
2013
Q3 | $10.6M | Buy |
529,504
+69,776
| +15% | +$1.32M | 0.25% | 94 |
|
|
2013
Q2 | $7.94M | Buy |
+459,728
| New | +$7.63M | 0.16% | 95 |
|
Other funds holding TECH
HI
Geneva Capital Management's TECH Position: Q2 2026 in Review
Geneva Capital Management reduced its Bio-Techne (TECH) stake by 19% in Q2 2026, selling an estimated $12.5M and leaving 1,012,077 shares worth $71.5M. The position accounts for 1.64% of the portfolio, ranked #20.
Geneva Capital Management first reported a position in TECH in Q2 2013 and has held it in 32 quarters since. The position peaked at $159M in Q2 2021. 593 funds tracked by Wall St. Rank hold TECH as of Q2 2026.
- Geneva Capital Management held 1,012,077 shares of Bio-Techne worth $71.5M as of Q2 2026.
- Geneva Capital Management sold 230,966 Bio-Techne shares in Q2 2026, an estimated $12.5M.
- Bio-Techne made up 1.64% of Geneva Capital Management's portfolio in Q2 2026, its #20 holding.
- Geneva Capital Management first reported a position in Bio-Techne in Q2 2013 and has held it in 32 quarters since.
- Geneva Capital Management's Bio-Techne position peaked at $159M in Q2 2021.
- 593 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.
Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.